



Voyager Therapeutics to Present at Investor Conferences in October

October 3, 2017

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:

- **Chardan Gene Therapy Conference, New York City**

Date: Tuesday, October 10, 2017

Time: 9:00 a.m. EDT

Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer

- **Jefferies Gene Technology Investor Summit, New York City**

Date: Thursday, October 12, 2017

Time: 3:30 p.m. EDT

Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Dinah Sah, Ph.D., chief scientific officer

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager's website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager's pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of ALS, Huntington's disease, Friedrich's ataxia, frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.

Investor Relations:

Matt Osborne

Head of Investor Relations & Corporate Communications

857-259-5353

mosborne@vygr.com

Media:

Katie Engleman

Pure Communications, Inc.

910-509-3977

Katie@purecommunicationsinc.com



Voyager Therapeutics